Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for AMR prevention in heart transplant
NCT02013037Phase 3Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Nov 2012
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in antibody mediated rejection (AMR), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction at 26 weeks. Started Nov 2012; status: completed.
02
Drugs
eculizumab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02013037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013037.